Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus PROMETRIUM.
GYNOREST vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category C
Category C
Progestin
Progestin